Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum: A Multi-Institutional Analysis

[1]  N. Machado,et al.  Large duodenal gastrointestinal stromal tumor presenting with acute bleeding managed by a whipple resection. A review of surgical options and the prognostic indicators of outcome. , 2011, JOP : Journal of the pancreas.

[2]  R. Pazdur,et al.  Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). , 2010, The oncologist.

[3]  A. Agaimy.  Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. , 2010, International journal of clinical and experimental pathology.

[4]  R. Pazdur,et al.  Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. , 2010, The oncologist.

[5]  J. Chung,et al.  Management and Outcome of Gastrointestinal Stromal Tumors of the Duodenum , 2010, Journal of Gastrointestinal Surgery.

[6]  T. Tsujinaka,et al.  Survival Analysis of Patients With Duodenal Gastrointestinal Stromal Tumors , 2010, Journal of clinical gastroenterology.

[7]  Xiao-Jun Yang,et al.  Duodenal gastrointestinal stromal tumor: Clinical, pathologic, immunohistochemical characteristics, and surgical prognosis , 2009, Journal of surgical oncology.

[8]  P. Morel,et al.  Surgical management of gastrointestinal stromal tumours , 2009, The British journal of surgery.

[9]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[10]  R. Mennigen,et al.  Segmental resection of the duodenum for gastrointestinal stromal tumor (GIST) , 2008, World journal of surgical oncology.

[11]  M. Asakawa,et al.  Simple segmental resection of the second portion of the duodenum for the treatment of gastrointestinal stromal tumors , 2008, Langenbeck's Archives of Surgery.

[12]  M. Federico,et al.  Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study , 2007, BMC Cancer.

[13]  P. Chow,et al.  Outcome after surgical treatment of suspected gastrointestinal stromal tumors involving the duodenum: Is limited resection appropriate? , 2007, Journal of Surgical Oncology.

[14]  S. Hirota,et al.  An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors , 2007, International Journal of Clinical Oncology.

[15]  C. Antonescu,et al.  Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors , 2007, Annals of Surgical Oncology.

[16]  Chien-Feng Li,et al.  A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. , 2007, Surgery.

[17]  P. Rutkowski,et al.  Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor , 2007, Annals of Surgical Oncology.

[18]  A. Munir,et al.  Metastatic duodenal GIST: role of surgery combined with imatinib mesylate , 2007, International seminars in surgical oncology : ISSO.

[19]  L. Mack,et al.  Local excision of duodenal gastrointestinal stromal tumor , 2007, Journal of surgical oncology.

[20]  P. Chow,et al.  Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  R. Winfield,et al.  Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum , 2006, The American surgeon.

[22]  J. Cameron,et al.  One Thousand Consecutive Pancreaticoduodenectomies , 2006, Annals of surgery.

[23]  F. Ris,et al.  An audit of surgical management of gastrointestinal stromal tumours (GIST). , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  J. Jónasson,et al.  Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification study , 2005, International journal of cancer.

[25]  J. Blay,et al.  Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[27]  A. Hagemeijer,et al.  Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site , 2004, Modern Pathology.

[28]  B. Eisenberg,et al.  Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy , 2004, Annals of Surgical Oncology.

[29]  E. Gaffney,et al.  Gastrointestinal stromal tumours , 2003, The British journal of surgery.

[30]  C. Ryan,et al.  Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. , 2003, Surgery.

[31]  G. Demetri,et al.  Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.

[32]  J. Fletcher,et al.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[34]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[35]  L. Sobin,et al.  Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 167 Cases , 2001, The American journal of surgical pathology.

[36]  B. Yeap,et al.  The effect of surgery and grade on outcome of gastrointestinal stromal tumors. , 2001, Archives of surgery.

[37]  R. Cheney,et al.  Gastrointestinal Stromal Tumors: Current Diagnosis, Biologic Behavior, and Management , 2000, Annals of Surgical Oncology.

[38]  L. Sobin,et al.  Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT) , 2000, Modern Pathology.

[39]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[40]  Po-Huang Lee,et al.  Surgery for Gastrointestinal Stromal Tumors of the Duodenum , 2009, Annals of Surgical Oncology.

[41]  J. Donohue,et al.  Surgically Managed Gastrointestinal Stromal Tumors: A Comparative and Prognostic Analysis , 2007, Annals of Surgical Oncology.

[42]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[43]  L. Sobin,et al.  Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. , 1999, The American journal of surgical pathology.

[44]  J. Goldblum,et al.  Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 cases. , 1995, The American journal of surgical pathology.

[45]  M. Makuuchi,et al.  Scenario 1 : Complication After a Surgical Procedure Not Caused by a Surgeon , 2022 .